Compass Pathways PLC Sponsored ADR $CMPS Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 169.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 424,800 shares of the company’s stock after acquiring an additional 266,908 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.44% of Compass Pathways worth $2,931,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CMPS. Simplify Asset Management Inc. acquired a new stake in Compass Pathways during the 3rd quarter valued at approximately $1,662,000. Jefferies Financial Group Inc. acquired a new position in shares of Compass Pathways in the 3rd quarter valued at approximately $7,890,000. Propel Bio Management LLC acquired a new position in shares of Compass Pathways in the 3rd quarter valued at approximately $2,922,000. Blue Owl Capital Holdings LP boosted its stake in shares of Compass Pathways by 163.1% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 604,914 shares of the company’s stock valued at $3,466,000 after buying an additional 375,000 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in shares of Compass Pathways by 28.6% during the 3rd quarter. ARK Investment Management LLC now owns 2,121,118 shares of the company’s stock valued at $12,154,000 after buying an additional 471,897 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. HC Wainwright increased their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Canaccord Genuity Group dropped their target price on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, March 26th. Finally, Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.63.

Compass Pathways Price Performance

Shares of CMPS opened at $5.52 on Wednesday. The firm has a market cap of $530.03 million, a price-to-earnings ratio of -1.79 and a beta of 1.90. The stock has a 50 day moving average of $6.58 and a 200-day moving average of $6.31. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 0.55. Compass Pathways PLC Sponsored ADR has a 52 week low of $2.25 and a 52 week high of $8.90.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.59). As a group, analysts forecast that Compass Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.